Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments
JL Mega, T Simon - The Lancet, 2015 - thelancet.com
Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …
treat many cardiovascular disorders and, as such, are some of the most commonly …
Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by …
Hypertension is a common cardiovascular risk factor leading to heart failure (HF), coronary
artery disease, stroke, peripheral artery disease and chronic renal insufficiency …
artery disease, stroke, peripheral artery disease and chronic renal insufficiency …
Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by …
Since the advent of the non-vitamin K antagonist oral anticoagulant (NOAC) agents, which
act as direct thrombin inhibitors or inhibitors of Factor Xa, clinicians are provided with …
act as direct thrombin inhibitors or inhibitors of Factor Xa, clinicians are provided with …
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European heart rhythm association (EHRA) and …
Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with
valvular heart disease (VHD) is also common. However, management strategies for this …
valvular heart disease (VHD) is also common. However, management strategies for this …
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013
Aims Non-vitamin K antagonist oral anticoagulation (NOAC) agents have been approved for
stroke prophylaxis in atrial fibrillation (AF). We investigated 'real-world'information on how …
stroke prophylaxis in atrial fibrillation (AF). We investigated 'real-world'information on how …
Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European heart rhythm association (EHRA) and ESC Council on …
GYH Lip, A Coca, T Kahan, G Boriani… - European Heart …, 2017 - academic.oup.com
Hypertension (HTN) is a common cardiovascular risk factor leading to heart failure (HF),
coronary artery disease (CAD), stroke, peripheral artery disease and chronic renal failure …
coronary artery disease (CAD), stroke, peripheral artery disease and chronic renal failure …
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
FWA Verheugt, CB Granger - The Lancet, 2015 - thelancet.com
In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists
reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations …
reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations …
Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control
A Janzic, M Kos - Pharmacoeconomics, 2015 - Springer
Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care
Abstract Background Atrial fibrillation affects 1–2% of the general population and 10% of
those over 75, and is responsible for around a quarter of all strokes. These strokes are …
those over 75, and is responsible for around a quarter of all strokes. These strokes are …
[HTML][HTML] Exploring indications for the use of direct oral anticoagulants and the associated risks of major bleeding
TJ Milling Jr, JA Frontera - The American journal of managed care, 2017 - ncbi.nlm.nih.gov
Thrombosis is a leading cause of morbidity and mortality in the United States. Arterial and
venous thromboses are implicated in the pathogenesis of major disorders, including …
venous thromboses are implicated in the pathogenesis of major disorders, including …